IL153229A0 - Method of administering bisphosphonates - Google Patents

Method of administering bisphosphonates

Info

Publication number
IL153229A0
IL153229A0 IL15322901A IL15322901A IL153229A0 IL 153229 A0 IL153229 A0 IL 153229A0 IL 15322901 A IL15322901 A IL 15322901A IL 15322901 A IL15322901 A IL 15322901A IL 153229 A0 IL153229 A0 IL 153229A0
Authority
IL
Israel
Prior art keywords
bisphosphonates
osteoporosis
potent
months
periods
Prior art date
Application number
IL15322901A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26952565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL153229(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL153229A0 publication Critical patent/IL153229A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
IL15322901A 2000-06-20 2001-06-18 Method of administering bisphosphonates IL153229A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59713500A 2000-06-20 2000-06-20
US26768901P 2001-02-09 2001-02-09
PCT/EP2001/006850 WO2001097788A2 (fr) 2000-06-20 2001-06-18 Methode d'administration de bisphosphonates

Publications (1)

Publication Number Publication Date
IL153229A0 true IL153229A0 (en) 2003-07-06

Family

ID=26952565

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15322901A IL153229A0 (en) 2000-06-20 2001-06-18 Method of administering bisphosphonates
IL153229A IL153229A (en) 2000-06-20 2002-12-02 Use of 1 hydroxy - 2 - (imidazole - 1 - yale) Ethane - 1, 1 - bisphosphonic acid, in the preparation of a drug for the treatment of conditions of abnormal increase of bone change

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153229A IL153229A (en) 2000-06-20 2002-12-02 Use of 1 hydroxy - 2 - (imidazole - 1 - yale) Ethane - 1, 1 - bisphosphonic acid, in the preparation of a drug for the treatment of conditions of abnormal increase of bone change

Country Status (25)

Country Link
US (1) US8052987B2 (fr)
EP (1) EP1296689B3 (fr)
JP (2) JP4722375B2 (fr)
KR (1) KR100864743B1 (fr)
CN (1) CN1272013C (fr)
AT (1) ATE304856T1 (fr)
AU (2) AU7410901A (fr)
BR (1) BR0111806A (fr)
CA (1) CA2410201C (fr)
CY (2) CY1113740T1 (fr)
CZ (1) CZ301972B6 (fr)
DE (1) DE60113537T3 (fr)
DK (1) DK1296689T3 (fr)
ES (2) ES2394211T3 (fr)
HK (1) HK1072539A1 (fr)
HU (1) HU228400B1 (fr)
IL (2) IL153229A0 (fr)
MX (1) MXPA02012682A (fr)
NO (1) NO330459B1 (fr)
NZ (1) NZ523086A (fr)
PL (1) PL203087B1 (fr)
PT (1) PT1591122E (fr)
SK (1) SK287278B6 (fr)
TW (1) TWI289451B (fr)
WO (1) WO2001097788A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8052987B2 (en) 2000-06-20 2011-11-08 Novartis Pharmaceuticals Corporation Method of administering bisphosphonates
EP1192945A3 (fr) * 2000-09-21 2004-03-03 Pfizer Products Inc. Utilisation d'un agoniste/antagoniste estrogénique pour traiter l'ostéoarthrite
NZ528659A (en) * 2001-04-03 2005-02-25 Royal Alexandra Hosp Children A drug for use in bone grafting
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
WO2004024166A1 (fr) * 2002-09-16 2004-03-25 Novartis Ag Methode de prevention ou de reduction de fractures secondaires consecutives a une fracture de la hanche
JP2006506365A (ja) * 2002-10-15 2006-02-23 ノバルティス アクチエンゲゼルシャフト ビスホスホネートの投与方法
ES2530791T3 (es) 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis
WO2005072746A1 (fr) * 2004-01-30 2005-08-11 Astellas Pharma Inc. Inhinbiteur récepteur p2x
EP1713489B1 (fr) * 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Forme cristalline de sodium d'ibandronate et ses procedes de preparation
NZ555316A (en) * 2004-12-09 2009-08-28 Merck & Co Inc Estrogen receptor modulators
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US20090075941A1 (en) * 2006-04-21 2009-03-19 The Uab Research Foundation Treating neoplasms
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
US20100068211A1 (en) * 2008-02-08 2010-03-18 Bateman Ted A Use of antiresorptive compounds to prevent ionizing radiation-induced activation of osteoclasts and resulting bone loss
CA2723541A1 (fr) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions de peptides et leurs procedes de preparation
CA2751854A1 (fr) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition contenant un bisphosphonate et administration d'un medicament a base de bisphosphonate
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
IN2012DN01216A (fr) 2009-07-31 2015-04-10 Thar Pharmaceuticals Inc
DK2473172T3 (en) 2009-09-01 2015-06-15 Univ Duke BISPHOSPHONATSAMMENSÆTNINGER and Methods for treating congestive heart failure
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (fr) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Compositions pharmaceutiques d'inhibiteurs de facteur xa sélectifs destinées à une administration orale
WO2012071517A2 (fr) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Nouvelles formes cristallines
BR112013017169A2 (pt) 2011-01-07 2016-10-04 Merrion Res Iii Ltd composições farmacêuticas de ferro para administração oral
JP6261512B2 (ja) 2011-11-16 2018-01-17 デューク ユニバーシティ 心機能障害を治療及び／又は低減するためのビスホスホネート組成物並びに方法
CN103623465B (zh) * 2013-11-21 2015-12-30 彭江 一种可局部调节成破骨活性的组织工程骨支架及制备方法
EP3250191B1 (fr) 2015-01-29 2024-01-17 Novo Nordisk A/S Comprimés contenant un agoniste de glp-1 et revêtement gastro-résistant
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
KR20180115979A (ko) * 2017-04-14 2018-10-24 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
GB201716716D0 (en) 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles
WO2020093069A1 (fr) * 2018-11-02 2020-05-07 Ampersand Biopharmaceuticals, Inc. Gestion du risque de surcharge cationique et de déséquilibre électrolytique avec des agents tampons appliqués par voie topique
KR102049233B1 (ko) * 2019-01-14 2019-11-28 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594329A (en) * 1897-11-23 Socket or collet
DE3232959A1 (de) 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Substituierte benzolsulfonsaeureester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3587956T2 (de) 1984-04-30 1995-05-24 Procter & Gamble Ausrüstung für die Verwendung bei der Behandlung von Osteoporose.
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE10199052I1 (de) * 1986-11-21 2002-01-10 Novartis Ag Neue substituierte Alkandiphosphonsaeuren
HUT68010A (en) * 1991-12-17 1995-05-29 Procter & Gamble Pharma The use of bisphonates and parathyroid hormone for the treatment of osteoporosis
WO1994000129A1 (fr) 1992-06-30 1994-01-06 Procter & Gamble Pharmaceuticals, Inc. Utilisation de phosphonates dans le traitement de l'osteoporose
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
EP0600834A1 (fr) 1992-11-30 1994-06-08 Ciba-Geigy Ag Utilisation de dérivés de l'acide méthanediphosphonique pour la fabrication d'un médicament pour le traitement de fractures
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
JPH10505090A (ja) 1994-09-09 1998-05-19 ザ、プロクター、エンド、ギャンブル、カンパニー 骨活性ホスホネート及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
AU686019B2 (en) 1994-09-09 1998-01-29 Procter & Gamble Company, The Phosphonates and parathyroid hormone for osteoporosis
DE69634487T2 (de) 1995-09-29 2006-01-05 Novartis Ag Verfahren zur behandlung navikularer krankheiten bei pferden
US5735810A (en) 1996-06-14 1998-04-07 Becton Dickinson And Company Device for the iontophoretic administration of bisphosphonates
US5730715A (en) * 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
DK1175904T3 (da) 1997-07-22 2007-05-07 Merck & Co Inc Alendronat til anvendelse til behandling af osteoporose
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
SE9703691D0 (sv) 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
GB2336311A (en) 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
CA2308532C (fr) 1999-05-12 2005-11-29 Gador S.A. Emploi de bisphosphonates pour traiter l'osteogenese imparfaite
ATE293450T1 (de) 1999-05-21 2005-05-15 Novartis Pharma Gmbh Verwendung von biphosphonsäuren zur behandlung von angiogenese
IL142515A0 (en) * 1999-12-20 2002-03-10 Merck & Co Inc Pharmaceutical kit
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
US8052987B2 (en) 2000-06-20 2011-11-08 Novartis Pharmaceuticals Corporation Method of administering bisphosphonates

Also Published As

Publication number Publication date
NO20026117L (no) 2002-12-19
DE60113537T2 (de) 2006-06-29
NO20026117D0 (no) 2002-12-19
TWI289451B (en) 2007-11-11
ES2394211T3 (es) 2013-01-23
DE60113537T3 (de) 2013-05-29
IL153229A (en) 2007-07-24
CY1113740T1 (el) 2015-08-05
DK1296689T3 (da) 2005-11-28
WO2001097788A2 (fr) 2001-12-27
EP1296689B1 (fr) 2005-09-21
CA2410201A1 (fr) 2001-12-27
AU2001274109B2 (en) 2004-12-23
JP2005247873A (ja) 2005-09-15
CN1620300A (zh) 2005-05-25
AU7410901A (en) 2002-01-02
KR100864743B1 (ko) 2008-10-22
HUP0301164A3 (en) 2005-11-28
PL203087B1 (pl) 2009-08-31
NZ523086A (en) 2007-07-27
CZ301972B6 (cs) 2010-08-18
SK18082002A3 (sk) 2003-08-05
PL358224A1 (en) 2004-08-09
ATE304856T1 (de) 2005-10-15
EP1296689A2 (fr) 2003-04-02
JP4722375B2 (ja) 2011-07-13
CZ20024134A3 (cs) 2003-06-18
KR20030015283A (ko) 2003-02-20
WO2001097788A3 (fr) 2002-06-27
CA2410201C (fr) 2010-10-26
HK1072539A1 (en) 2005-09-02
US8052987B2 (en) 2011-11-08
DE60113537D1 (de) 2006-02-02
PT1591122E (pt) 2012-12-12
CN1272013C (zh) 2006-08-30
JP5005188B2 (ja) 2012-08-22
NO330459B1 (no) 2011-04-18
ES2247123T3 (es) 2006-03-01
HU228400B1 (en) 2013-03-28
BR0111806A (pt) 2003-05-20
HUP0301164A2 (hu) 2003-08-28
CY2013011I2 (el) 2015-08-05
JP2003535889A (ja) 2003-12-02
ES2247123T7 (es) 2013-03-01
CY2013011I1 (el) 2015-08-05
SK287278B6 (sk) 2010-05-07
US20030181421A1 (en) 2003-09-25
MXPA02012682A (es) 2003-04-25
EP1296689B3 (fr) 2013-02-13

Similar Documents

Publication Publication Date Title
AU7410901A (en) Method of administering bisphosphonates
CY1106482T1 (el) Φαρμακευτικη παρεντepικη συνθεση πepιεχοντας ενα διφωσφονικο
NZ527157A (en) Compositions for delivering bisphosphonates
ZA929712B (en) Prevention and treatment of peridontal disease with alendronate.
MY140080A (en) Treatment and prevention of osteoporosis
IL155363A0 (en) Use of bisphosphonates for pain treatment
DK0756484T3 (da) Vådgranuleringsformulering til diphosphonsyrer
DE69905488D1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
PL351674A1 (en) Use of bisphosphonic acids for treating angiogenesis
HUP0004653A2 (hu) Biszfoszfonátok alkalmazása csontreszorpció gátlására szolgáló gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
NP Permission for amending the patent specification granted (section 66, patents law 1967)